Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

BMC Pulmonary Medicine

Shenyi Zhang¹  Liyuan Song¹  Wang Cheng¹  Hao Liu¹  Hong Xia¹  Xihua Li¹  Fuyun Ji²  Yi Wu³  Huzi Zhao⁴  Xuejiao Tai⁴  Xianhui Wang⁵  Ruizi Liu⁶  Min Liu⁷ 

[1] Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Science, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;Taihe Hospital, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;Department of Pathology, School of Basic Medical Science, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;Institute of Biomedical Research, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;School of Clinical Medicine, Shandong First Medical University, 250000, Jinan, Shandong Province, China;Taihe Hospital, Hubei University of Medicine, 442000, Shiyan, Hubei Province, China;

关键词: CTSF;    NSCLC;    Prognosis;    Immune response;    Immunotherapy;   

DOI  :  10.1186/s12890-021-01796-w

来源: Springer

【 摘 要 】

BackgroundIn recent years, immunotherapies and targeted therapies contribute to population-level improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options have mainly benefit patients containing mutated driven genes. Thus, to explore other potential genes related with immunity or targeted therapies may provide novel options to improve survival of lung cancer patients without mutated driven genes. CTSF is unique in human cysteine proteinases. Presently, CTSF has been detected in several cell lines of lung cancer, but its role in progression and prognosis of lung cancer remains unclear.MethodsCTSF expression and clinical datasets of lung cancer patients were obtained from GTEx, TIMER, CCLE, THPA, and TCGA, respectively. Association of CTSF expression with clinicopathological parameters and prognosis of lung cancer patients was analyzed using UALCAN and Kaplan–Meier Plotter, respectively. LinkedOmics were used to analyze correlation between CTSF and CTSF co-expressed genes. Protein–protein interaction and gene–gene interaction were analyzed using STRING and GeneMANIA, respectively. Association of CTSF with molecular markers of immune cells and immunomodulators was analyzed with Immunedeconv and TISIDB, respectively.ResultsCTSF expression was currently only available for patients with NSCLC. Compared to normal tissues, CTSF was downregulated in NSCLC samples and high expressed CTSF was correlated with favorable prognosis of NSCLC. Additionally, CTSF expression was correlated with that of immune cell molecular markers and immunomodulators both in LUAD and LUSC. Noticeably, high expression of CTSF-related CTLA-4 was found to be associated with better OS of LUAD patients. Increased expression of CTSF-related LAG-3 was related with poor prognosis of LUAD patients while there was no association between CTSF-related PD-1/PD-L1 and prognosis of LUAD patients. Moreover, increased expression of CTSF-related CD27 was related with poor prognosis of LUAD patients while favorable prognosis of LUSC patients.ConclusionsCTSF might play an anti-tumor effect via regulating immune response of NSCLC.

【 授权许可】

CC BY